George Rehm, J.D.

​

Mr. George Rehm has over 30 years of experience as a lawyer and executive in international licensing, technology transfer, investment and privatization transactions in the US, Europe and Asia. He worked as legal counsel for numerous international technology transfer transactions and served as chief European consultant to Bristol-Myers Squibb on a clinical oncology care project, focused on the EU. He was a founding partner of aeris CAPITAL AG, financial advisor to a large European family office, where he established its healthcare investing strategy, including venture, private equity, and hedge fund investments. Currently, he serves as an Advisor and Partner in Healthspottr LLC. He has held board or observer positions in numerous transformational healthcare companies, including Crescendo Biosciences (now Myriad Genetics), Adamas Pharmaceuticals (IPO 2014), Ion Torrent, Inc. (now Thermo-Fisher), GenomeDx (now Decipher, acquired by Veracyte Inc. 2021), Butterfly Networks (IPO, 2020), Hyperfine Research (SPAC IPO, 2021), Quantum SI (SPAC IPO, 2021), Jiff (now Castlight Health) and Tethys Biosciences.  Currently, from a base in Northern California, he is a lecturer in the Business Law Program at Berkeley Law, and advisor to UC Berkeley School of Public Health, while serving as an advisor to Jonathan Rothberg’s 4Catalyzer incubator.  He also serves as a director and advisor to Vive Benefits, MyOwn MEd, and PFS Genetics (acquired by Exact Sciences, 2021), as well as Artera Inc., and Chromatic.  Mr. Rehm has written and lectured frequently in Germany and the US on international trade, investment, technology transfer, health care, and venture capital and is fluent in both German and English.